Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumabresistance in HER2-positive breast cancer
Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumabresistance in HER2-positive breast cancer
复制标题
癌症干细胞靶向治疗方法可克服 HER2 阳性乳腺癌的曲妥珠单抗耐药性
DOI：
10.1002/stem.3381
复制
发表时间：
2021-04-20
期刊：
影响因子：
5.2
通讯作者：
Luo, Xiaobo
中科院分区：
文献类型：
--
作者：
Qiu, Yan;Yang, Libo;Luo, Xiaobo
抗HER2药物曲妥珠单抗的应用显着改善了HER2阳性亚型乳腺癌患者的预后。然而，50% HER2 扩增的患者由于曲妥珠单抗耐药而复发。越来越多的证据表明乳腺癌是由一小部分癌症起始细胞或乳腺癌干细胞（BCSC）驱动的，这些细胞具有自我更新和分化能力以再生肿瘤细胞层次结构。越来越多的数据表明，BCSC 对常规治疗（包括化疗、放疗和内分泌治疗）具有抵抗力，这会导致远处转移和乳腺癌复发。近年来，乳腺癌的曲妥珠单抗耐药与BCSC的患病率密切相关。在这里，我们的主要重点是讨论 BCSC 上皮间质转化 (EMT) 在曲妥珠单抗耐药情况下的作用以及减少或根除 HER2 阳性乳腺癌中 BCSC 的方法。
Application of the anti-HER2 drug trastuzumab has significantly improved the prognosis of patients with the HER2-positive subtype of breast cancer. However, 50% of patients with HER2 amplification relapse due to trastuzumab resistance. Accumulating evidence indicates that breast cancer is driven by a small subset of cancer-initiating cells or breast cancer stem cells (BCSCs), which have the capacity to self-renew and differentiate to regenerate the tumor cell hierarchy. Increasing data suggest that BCSCs are resistant to conventional therapy, including chemotherapy, radiotherapy, and endocrine therapy, which drives distant metastasis and breast cancer relapse. In recent years, the trastuzumab resistance of breast cancer has been closely related to the prevalence of BCSCs. Here, our primary focus is to discuss the role of epithelial-mesenchymal transition (EMT) of BCSCs in the setting of trastuzumab resistance and approaches of reducing or eradicating BCSCs in HER2-positive breast cancer.